We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seelos Therapeutics Inc | NASDAQ:SEEL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0056 | -1.94% | 0.2834 | 0.2751 | 0.2834 | 0.3134 | 0.2705 | 0.2947 | 180,376 | 16:31:45 |
| | |
Per Share
|
| |
Total
|
| ||||||
Offering price
|
| | | $ | 1.175 | | | | | $ | 4,000,000.80 | | |
Placement agent’s fees(1)
|
| | | $ | 0.08225 | | | | | $ | 280,000.06 | | |
Proceeds to us, before expenses(2)
|
| | | $ | 1.09275 | | | | | $ | 3,720,000.74 | | |
| | |
Page
|
| |||
| | | | S-1 | | | |
| | | | S-2 | | | |
| | | | S-9 | | | |
| | | | S-11 | | | |
| | | | S-13 | | | |
| | | | S-15 | | | |
| | | | S-16 | | | |
| | | | S-17 | | | |
| | | | S-18 | | | |
| | | | S-20 | | | |
| | | | S-21 | | | |
| | | | S-23 | | | |
| | | | S-25 | | | |
| | | | S-25 | | | |
| | | | S-26 | | | |
| | | | S-26 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 10 | | | |
| | | | | 15 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 23 | | | |
| | | | | 32 | | | |
| | | | | 36 | | | |
| | | | | 37 | | | |
| | | | | 38 | | | |
| | | | | 41 | | | |
| | | | | 43 | | | |
| | | | | 43 | | | |
| | | | | 43 | | | |
| | | | | 44 | | |
|
Product
|
| |
Indication
|
| |
Development
Phase |
| |
Development Status
|
|
|
SLS-002
Intranasal Racemic Ketamine |
| |
Acute Suicidal Ideation and Behavior (“ASIB”) in Major Depressive Disorder (“MDD”)
|
| |
Phase II
|
| |
Completed open-label patient enrollment and announced the initial topline data from Part 1 of the proof-of-concept (“PoC”) study on May 17, 2021; enrollment of Part 2 of a Phase II study closed in June 2023; topline data for Part 2 announced on September 20, 2023
|
|
|
SLS-005
IV Trehalose |
| |
Amyotrophic Lateral Sclerosis (“ALS”)
|
| |
Phase II/III
|
| |
Completed enrollment of final participants in February 2023 in the registrational study; data readout expected in the first quarter of 2024
|
|
| | | |
Spinocerebellar Ataxia (“SCA”)
|
| |
Phase IIb/III
|
| |
Announced dosing of the first participant in the registrational study in October 2022; enrollment of additional patients temporarily paused on March 29, 2023
|
|
| | | |
Huntington’s Disease (“HD”) and Alzheimer’s Disease (“AD”)
|
| |
Phase II
|
| |
Obtaining biomarker activity
|
|
|
SLS-004
|
| |
Parkinson’s Disease (“PD”)
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing; announced partial results from a study demonstrating downregulation of α-synuclein in December 2022; currently analyzing data while temporarily pausing additional spend
|
|
|
Product
|
| |
Indication
|
| |
Development
Phase |
| |
Development Status
|
|
|
Gene Therapy
SLS-007 |
| |
PD
|
| |
Pre-IND
|
| |
Preclinical study completed and analysis of the results ongoing; next steps for development of this program will be decided in concert with SLS-004 results and readouts, as both target the same pathway upstream; temporarily pausing additional spend
|
|
|
Peptide Inhibitor
|
| | | | | | | | | |
|
SLS-009
|
| |
HD, AD, ALS
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing
|
|
|
Offering price per share of common stock
|
| | | | | | | | | $ | 1.175 | | |
|
Net tangible book value per share as of September 30, 2023
|
| | | $ | (5.72) | | | | | | | | |
|
Increase in net tangible book value per share attributable to the issuance of an aggregate of 754,863 shares of our common stock issued to the holder of the Note to satisfy principal and interest payments thereunder between October 5, 2023 and January 12, 2024; 155 shares of our common stock issued as a result of the Reverse Stock Split; 1,781,934 shares of our common stock issued on December 1, 2023 pursuant to the Underwriting Agreement; and 2,422,612 shares of our common stock issued between December 1, 2024 and December 4, 2024 pursuant to the exercise of the December Pre-Funded Warrants
|
| | | $ | 3.43 | | | | | | | | |
|
Pro forma net tangible book value per share as of September 30, 2023
|
| | | $ | (2.29) | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | 0.83 | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share as of September 30, 2023, after giving effect to this offering
|
| | | | | | | | | $ | (1.46) | | |
|
Dilution per share to investors participating in this offering
|
| | | | | | | | | $ | 2.635 | | |
| | |
Per Share
|
| |
Total
|
| ||||||
Offering price
|
| | | $ | 1.175 | | | | | $ | 4,000,000.80 | | |
Placement agent’s fees(1)
|
| | | $ | 0.08225 | | | | | $ | 280.000.06 | | |
Proceeds to us, before expenses(2)
|
| | | $ | 1.09275 | | | | | $ | 3,720,000.74 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 10 | | | |
| | | | 15 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 23 | | | |
| | | | 32 | | | |
| | | | 36 | | | |
| | | | 37 | | | |
| | | | 38 | | | |
| | | | 41 | | | |
| | | | 43 | | | |
| | | | 43 | | | |
| | | | 43 | | | |
| | | | 44 | | |
Product
|
| |
Indication
|
| |
Development
Phase |
| |
Development Status
|
|
SLS-002
Intranasal Racemic Ketamine |
| |
Acute Suicidal Ideation and Behavior (“ASIB”) in Major Depressive Disorder (“MDD”)
|
| |
Phase II
|
| |
Completed open-label patient enrollment
and announced the initial topline data from Part 1 of the proof-of-concept (“PoC”) study on May 17, 2021; enrollment of Part 2 of a Phase II study closed in June 2023; topline data for Part 2 announced on September 20, 2023 |
|
SLS-005
IV Trehalose |
| |
Amyotrophic Lateral Sclerosis (“ALS)”
|
| |
Phase II/III
|
| |
Completed enrollment of final
participants in February 2023 in the registrational study; data readout expected in the first quarter of 2024 |
|
| | |
Spinocerebellar Ataxia (“SCA”)
|
| |
Phase IIb/III
|
| |
Announced dosing of the first
participant in the registrational study in October 2022; enrollment of additional patients temporarily paused on March 29, 2023 |
|
| | |
Huntington’s Disease (“HD”) and Alzheimer’s Disease (“AD”)
|
| |
Phase II
|
| |
Obtaining biomarker activity
|
|
Product
|
| |
Indication
|
| |
Development
Phase |
| |
Development Status
|
|
SLS-004
Gene Therapy |
| |
Parkinson’s Disease (“PD”)
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing;
announced partial results from a study demonstrating downregulation of α-synuclein in December 2022; currently analyzing data while temporarily pausing additional spend |
|
SLS-007
Peptide Inhibitor |
| |
PD
|
| |
Pre-IND
|
| |
Preclinical study completed and
analysis of the results ongoing; next steps for development of this program will be decided in concert with SLS-004 results and readouts, as both target the same pathway upstream; temporarily pausing additional spend |
|
SLS-009 | | |
HD, AD, ALS
|
| |
Pre-IND
|
| |
Preclinical in vivo studies ongoing
|
|
1 Year Seelos Therapeutics Chart |
1 Month Seelos Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions